CN1537007A - 甲基-噻吩并-苯并二氮杂�的冻干制剂 - Google Patents

甲基-噻吩并-苯并二氮杂�的冻干制剂 Download PDF

Info

Publication number
CN1537007A
CN1537007A CNA028144473A CN02814447A CN1537007A CN 1537007 A CN1537007 A CN 1537007A CN A028144473 A CNA028144473 A CN A028144473A CN 02814447 A CN02814447 A CN 02814447A CN 1537007 A CN1537007 A CN 1537007A
Authority
CN
China
Prior art keywords
formulation
olanzapine
tartaric acid
dsm
lactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028144473A
Other languages
English (en)
Chinese (zh)
Inventor
K��D���¿���
K·D·德坎珀
A·L·费特斯
ζ���ԣ
S·L·奈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1537007A publication Critical patent/CN1537007A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNA028144473A 2001-07-20 2002-07-05 甲基-噻吩并-苯并二氮杂�的冻干制剂 Pending CN1537007A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US60/306,829 2001-07-20
US38647402P 2002-06-07 2002-06-07
US60/386,474 2002-06-07

Publications (1)

Publication Number Publication Date
CN1537007A true CN1537007A (zh) 2004-10-13

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028144473A Pending CN1537007A (zh) 2001-07-20 2002-07-05 甲基-噻吩并-苯并二氮杂�的冻干制剂

Country Status (32)

Country Link
US (1) US20040176357A1 (https=)
EP (1) EP1423124B1 (https=)
JP (1) JP2004537546A (https=)
KR (1) KR20040017330A (https=)
CN (1) CN1537007A (https=)
AR (1) AR036180A1 (https=)
AT (1) ATE369137T1 (https=)
AU (1) AU2002320134B2 (https=)
BR (1) BR0211250A (https=)
CA (1) CA2448724A1 (https=)
CO (1) CO5540279A2 (https=)
CY (1) CY1107759T1 (https=)
CZ (1) CZ200484A3 (https=)
DE (1) DE60221674T2 (https=)
DK (1) DK1423124T3 (https=)
EA (1) EA006506B1 (https=)
ES (1) ES2289126T3 (https=)
HR (1) HRP20040037A2 (https=)
HU (1) HUP0401157A3 (https=)
IL (1) IL159098A0 (https=)
MX (1) MXPA04000541A (https=)
MY (1) MY135452A (https=)
NZ (1) NZ529667A (https=)
PE (1) PE20030281A1 (https=)
PL (1) PL366614A1 (https=)
PT (1) PT1423124E (https=)
SI (1) SI1423124T1 (https=)
SK (1) SK182004A3 (https=)
SV (1) SV2003001179A (https=)
UA (1) UA80095C2 (https=)
WO (1) WO2003007912A2 (https=)
ZA (1) ZA200400798B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323459B2 (en) * 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
HU226410B1 (en) 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421297B1 (en) * 1989-09-30 1993-12-01 Eisai Co., Ltd. Injectable preparations containing cephalosporin medicament and the use thereof
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Also Published As

Publication number Publication date
CY1107759T1 (el) 2013-06-19
EA006506B1 (ru) 2005-12-29
HUP0401157A3 (en) 2008-01-28
HUP0401157A2 (hu) 2004-10-28
AR036180A1 (es) 2004-08-18
EA200400211A1 (ru) 2004-06-24
BR0211250A (pt) 2004-07-27
DE60221674D1 (de) 2007-09-20
WO2003007912A2 (en) 2003-01-30
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
PT1423124E (pt) 2007-10-29
PL366614A1 (en) 2005-02-07
EP1423124A2 (en) 2004-06-02
MXPA04000541A (es) 2004-05-04
JP2004537546A (ja) 2004-12-16
CZ200484A3 (cs) 2005-01-12
EP1423124B1 (en) 2007-08-08
DK1423124T3 (da) 2007-12-03
PE20030281A1 (es) 2003-03-27
KR20040017330A (ko) 2004-02-26
HK1066484A1 (en) 2005-03-24
CA2448724A1 (en) 2003-01-30
SI1423124T1 (sl) 2008-02-29
HRP20040037A2 (en) 2004-06-30
WO2003007912A3 (en) 2003-05-01
CO5540279A2 (es) 2005-07-29
DE60221674T2 (de) 2008-04-30
UA80095C2 (en) 2007-08-27
SK182004A3 (en) 2004-09-08
NZ529667A (en) 2006-02-24
ATE369137T1 (de) 2007-08-15
AU2002320134B2 (en) 2007-04-05
ZA200400798B (en) 2005-07-27
IL159098A0 (en) 2004-05-12
US20040176357A1 (en) 2004-09-09
ES2289126T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
TWI489984B (zh) 用於非經腸道傳輸化合物之配方及其用途
JP5990832B2 (ja) デキスメデトミジンプレミックス製剤
CN101511342A (zh) 干粉化合物制剂及其用途
KR101762285B1 (ko) 암 및 다른 질환 또는 장애의 치료용 약제학적 조성물
CZ284363B6 (cs) Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů
CZ212094A3 (en) The use of 2-amino-6-trifluoromethoxybenzothiazole for obtaining a medicament determined for treating diseases of motor neuron
CN1479617A (zh) N-甲基-d-天冬氨酸受体拮抗剂的药物组合物
CN102813621A (zh) 帕洛诺司琼液体药物配方
CN1537007A (zh) 甲基-噻吩并-苯并二氮杂�的冻干制剂
CN103202815A (zh) 治疗精神疾病的注射剂
AU2002320134A1 (en) Lyophilized formulation comprising olanzapine
JP2007508313A (ja) メチルフェニデート溶液および関連する投与および製造方法
CN1230164C (zh) (S)－2－(苄基氨基甲基)－2,3,8,9－四氢－7H－1,4－二英并[2,3－e]吲哚－8－酮和精神抑制药的用于治疗或预防精神病的新的治疗剂组合物
HK1066484B (en) Lyophilized formulation comprising olanzapine
US20250319066A1 (en) Injectable dmt formulations
HK40063844A (en) Pharmaceutical composition and use thereof
HK1088839A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication